Sarlósejtes vérszegénység: vizsgálatok itt: Szaúd-Arábia
6 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- No phaseTaking peopleEfficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis
- Where
- Dammam, Dhahran, Jubail, Riyadh
- Életkor
- 18 év to 60 év
- People
- 394
- Run by
- Imam Abdulrahman Bin Faisal University
See details and how to joinNCT07188766 - 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Riyadh
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Jizan, Riyadh
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisTaking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Al Ahsa, Al Qaţīf, Dhahran, Riyadh
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 2/3. fázisNot yet taking people in Szaúd-ArábiaA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Riyadh
- Életkor
- 12 év to 64 év
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00 - 3. fázisTaking peopleEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- Where
- Al Mathar Ash Shamali
- Életkor
- 12 év to 35 év
- People
- 26 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT05477563 · EU 2024-514641-12-00